One-year tumor volume regression (TVR) after low-dose-rate iodine-125 plaque brachytherapy predicts overall survival in patients with uveal melanoma.
Intermediate tumor regression (33.3% to 75% volume reduction) associates with the best survival outcomes compared to delayed or accelerated regression.
TVR measurement using ultrasound-derived ellipsoid modeling provides a practical biomarker for risk stratification and patient counseling.
